Vickie A Marshall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4344036/publications.pdf

Version: 2024-02-01

516710 526287 28 776 16 27 citations g-index h-index papers 29 29 29 888 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Advances, 2021, 5, 1660-1670.	5.2	35
2	Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. Nature Communications, 2021, 12, 7323.	12.8	13
3	Risk Factors for Kaposi's Sarcoma–Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda. Clinical Infectious Diseases, 2020, 71, 1055-1062.	5. 8	19
4	Dual infection and recombination of Kaposi sarcoma herpesvirus revealed by whole-genome sequence analysis of effusion samples. Virus Evolution, 2020, 6, veaa047.	4.9	5
5	Distinct genetic architectures and environmental factors associate with host response to the \hat{l}^3 2-herpesvirus infections. Nature Communications, 2020, 11, 3849.	12.8	24
6	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease. Blood, 2020, 135, 2316-2319.	1.4	33
7	Everolimus-Induced Remission of Classic Kaposi's Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency. Journal of Clinical Immunology, 2020, 40, 774-779.	3.8	5
8	Signatures of oral microbiome in HIV-infected individuals with oral Kaposi's sarcoma and cell-associated KSHV DNA. PLoS Pathogens, 2020, 16, e1008114.	4.7	31
9	Epstein–Barr virus load is higher in longâ€term Hodgkin lymphoma survivors compared to their unaffected twins and unrelated controls. British Journal of Haematology, 2019, 185, 377-380.	2.5	1
10	Mutual detection of Kaposi's sarcomaâ€associated herpesvirus and Epstein–Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma. International Journal of Cancer, 2019, 145, 2468-2477.	5.1	30
11	Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon. Genes and Immunity, 2019, 20, 684-689.	4.1	10
12	The Contribution of Kaposi's Sarcoma–Associated Herpesvirus to Mortality in Hospitalized Human Immunodeficiency Virus–Infected Patients Being Investigated for Tuberculosis in South Africa. Journal of Infectious Diseases, 2019, 220, 841-851.	4.0	11
13	Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. Cancer Epidemiology, 2018, 52, 70-74.	1.9	17
14	Genome-Wide Sequence Analysis of Kaposi Sarcoma-Associated Herpesvirus Shows Diversification Driven by Recombination. Journal of Infectious Diseases, 2018, 218, 1700-1710.	4.0	25
15	Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers. Journal of Infectious Diseases, 2018, 218, 892-900.	4.0	21
16	Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	13
17	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. PLoS Pathogens, 2018, 14, e1007130.	4.7	10
18	Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions. Oncotarget, 2018, 9, 35856-35869.	1.8	5

#	Article	IF	CITATIONS
19	IL-13 Expression Characterizes Effusions Associated with Primary Effusion Lymphoma but Not Other Disorders Caused By Kaposi Sarcoma Herpesvirus (KSHV). Blood, 2018, 132, 4137-4137.	1.4	0
20	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. Oncologist, 2017, 22, 505-e49.	3.7	20
21	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clinical Infectious Diseases, 2016, 62, 730-738.	5.8	135
22	Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome. PLoS Pathogens, 2014, 10, e1004046.	4.7	57
23	Kaposi's Sarcoma-Associated Herpesvirus MicroRNA Single-Nucleotide Polymorphisms Identified in Clinical Samples Can Affect MicroRNA Processing, Level of Expression, and Silencing Activity. Journal of Virology, 2013, 87, 12237-12248.	3.4	22
24	Sequence Analysis of Kaposi Sarcoma–Associated Herpesvirus (KSHV) MicroRNAs in Patients with Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome. Journal of Infectious Diseases, 2012, 205, 1665-1676.	4.0	33
25	Kaposi Sarcoma (KS)–Associated Herpesvirus MicroRNA Sequence Analysis and KS Risk in a European AIDSâ€KS Case Control Study. Journal of Infectious Diseases, 2010, 202, 1126-1135.	4.0	26
26	Conservation of Virally Encoded MicroRNAs in Kaposi Sarcoma–Associated Herpesvirus in Primary Effusion Lymphoma Cell Lines and in Patients with Kaposi Sarcoma or Multicentric Castleman Disease. Journal of Infectious Diseases, 2007, 195, 645-659.	4.0	95
27	Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations. Journal of General Virology, 2004, 85, 155-163.	2.9	78
28	Systematic Analysis of Kaposi's Sarcomaâ€associated Herpesvirus Genomes from a Kaposi's Sarcoma (KS) Caseâ€Control Study in Cameroon: Evidence of Dual Infections but No Association Between Viral Sequence Variation and KS Risk. International Journal of Cancer, 0, , .	5.1	1